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LETTER TO THE EDITOR
Cervical cancer screening
Sir - Over the years, the British Journal of Cancer has
published a number of important papers on model-based
evaluation of cervical screening. Gustafsson and Adami
(1989) present an interesting technique for identification of
the natural history of cervical cancer, and use data from
Sweden to estimate the duration of carcinoma in situ (CIS)
and the proportion of these lesions which will regress spon-
taneously. The paper exemplifies very well how routinely
collected data on incidence and mortality can be used to
determine the natural history of CIS. This is important in
view of questions related to early detection. However, we
have our reservations about one of the main findings of the
paper: the low (12.2%) progression rate of new cases of
carcinoma in situ. The authors do not calculate expected
detection rates of CIS from the model. This would have
enabled direct validation of the model assumptions against
results reported by screening projects. The detection rates for
the first screening can be calculated as follows. Taking the
age-specific incidence (presented in Figure 7 in the paper),
and the values for (total) duration and progression of CIS
(from Table I in the paper), the age-specific prevalence of
CIS attains values between 3% and 4% in the age group
30-45. The sensitivity in the CIS states (Si,,) is not clearly
stated, but probably has a value of about 75%, when assum-
ing that the sensitivity for the invasive state is 100%
(Sinv= 1) and taking the mean of the two reported values I
and 2 for the ratio Sinv/Sinv This would mean a detection rate
at first screening of between 25 and 30 per 1,000 women at
their first Pap smear.
In comparison with data from screening projects in
Sweden and other countries, this figure is extremely high (see
Table I). Only the project in Malmo reports a figure within
this range, but other (larger) projects in Sweden report much
lower detection rates, which are more in agreement with
international data.
In our opinion, a model which is intended to assist in
designing cost-effective screening interventions should be
carefully validated against results of screening programmes.
This not only involves testing against detection rates at first
screening, but also more tedious testing against detection
rates at repeat screenings and against incidence rates of
invasive cancer following a negative Pap-smear.
Our tentative calculations point out that the reported pro-
gression rate of CIS is far too low. This is important for
evaluation of screening, since the finding of Gustafsson and
Adami would mean that 85% of the screen-detected cases of
CIS are treated unnecessarily. Furthermore, it could well be
that the other findings from the paper that were derived
simultaneously with the estimation of the progression rate,
such as the absence of age-dependency in the progression
rate and in the mean duration of CIS are no longer valid.
A second remark concerns the absence ofhysterectomies in
the model. Assuming the total female population to be at
risk of cervical cancer is not correct, since hysterectomies for
other causes than cervical cancer will reduce the actual risk
population. Very high hysterectomy rates, and considerable
time trends in these rates, have been reported from North
America and from European countries as well. The situation
in Sweden is not described in the paper. Part of the CIS cases
included in the cancer registry would not have been progress-
ed to invasive cervical cancer not because of spontaneous
regression, but because of intervention by a hysterectomy.
Thus, contrary to the definition given by the authors, the
model parameter P (progression rate of new CIS cases) will
not include all new in situ lesions that without therapeutic
measures would become invasive. As a consequence, the
'natural' progression rate will be somewhat higher than cal-
culated without considering hysterectomies.
Yours etc,
G.J. van Oortmarrsen & J.D.F. Habbema
Department of Public Health and Social
Medicine, Erasmus University,
PO Box 1738,
3000 DR Rotterdam,
The Netherlands.
Table I Detection rates at first screening from selected mass screening projects
Detection rate per No. screened
Project 1,000 screens x 1,000 Ages Stage Source
Stockholm 9.5 9.8 30-49 CIS Kjellgren (1977)
Vasterbotten 2.0a 22.5 30-49 CIS Kjellgren (1977)
Malmo 27.0 1.6 30-49 CIS Bjerre (1969)
Ostfold, Norway 5.3 24.3 30-49 CIS Magnus et al. (1987)
Finland 1.8" 315.0 40,45,50 CIS Hakama et al. (1975)
Nijmegen, Netherlands 3.1 45.5 35-53 CINIII van der Graafet al. (1988)
Br. Columbia 10.0 91.0 30-49 CIS Boyes et al. (1982)
aProbably including a non-negligible number of repeat smears.
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